Pfizer Inc. (PFE)

NYQ · Health Care · Drug Manufacturers - General
By Alex · Tickerpine
$24.29
+0.62 (+2.62%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$138.44B
P/E (TTM)
18.5
Forward P/E
8.6
EPS (TTM)
$1.31
ROE
8.31%
Profit Margin
11.83%
Revenue Growth
5.40%
Dividend Yield
7.08%
Beta
0.29
52W High
$28.75
52W Low
$23.11
Analyst Target
$29.15
What would an investment in PFE be worth today?
Run PFE through our free historical return calculator.
Calculate PFE returns →

Congress trading in PFE

41 members of Congress have disclosed trading PFE — 35 purchases and 42 sales worth an estimated $1.2M. Most recent disclosure: Feb 10, 2026.

See who in Congress traded PFE →

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company website ↗

PFE Key Statistics

Previous Close$23.67P/E Ratio18.5
Market Cap$138.44BPEG Ratio2.84
Revenue (TTM)$63.32BROE8.31%
Gross Margin74.80%ROA5.69%
Debt / Equity71.6Employees75,000

PFE in plain English

Compare PFE with peers

PFE vs LLYEli Lilly and Company $1,208.12 PFE vs JNJJohnson & Johnson $254.66 PFE vs ABBVAbbVie Inc. $253.35 PFE vs UNHUnitedHealth Group Incorporated $427.89 PFE vs MRKMerck & Co., Inc. $128.66

Data last refreshed from public sources. Figures may be delayed. Not investment advice.